PMID- 21067536
OWN - NLM
STAT- MEDLINE
DCOM- 20130212
LR  - 20231105
IS  - 1465-542X (Electronic)
IS  - 1465-5411 (Linking)
VI  - 12
IP  - 5
DP  - 2010
TI  - Antiangiogenic therapy for breast cancer.
PG  - 209
LID - 10.1186/bcr2642 [doi]
AB  - Angiogenesis is an important component of cancer growth, invasion and metastasis. 
      Therefore, inhibition of angiogenesis is an attractive strategy for treatment of 
      cancer. We describe existing clinical trials of antiangiogenic agents and the 
      challenges facing the clinical development and optimal use of these agents for 
      the treatment of breast cancer. Currently, the most promising approach has been 
      the use of bevacizumab, a humanized monoclonal antibody directed against the most 
      potent pro-angiogenic factor, vascular endothelial growth factor (VEGF). Small 
      molecular inhibitors of VEGF tyrosine kinase activity, such as sorafenib, appear 
      promising. While, the role of sunitinib and inhibitors of mammalian target of 
      rapamycin (mTOR) in breast cancer has to be defined. Several unanswered questions 
      remain, such as choice of drug(s), optimal duration of therapy and patient 
      selection criteria.
FAU - Nielsen, Dorte Lisbet
AU  - Nielsen DL
AD  - Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark. 
      dornie01@heh.regionh.dk
FAU - Andersson, Michael
AU  - Andersson M
FAU - Andersen, Jon Lykkegaard
AU  - Andersen JL
FAU - Kamby, Claus
AU  - Kamby C
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20100929
PL  - England
TA  - Breast Cancer Res
JT  - Breast cancer research : BCR
JID - 100927353
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Benzenesulfonates)
RN  - 0 (Indoles)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (Pyrroles)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Angiogenesis Inhibitors/pharmacology/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Benzenesulfonates/therapeutic use
MH  - Bevacizumab
MH  - Breast Neoplasms/*drug therapy
MH  - Female
MH  - Humans
MH  - Indoles/therapeutic use
MH  - Neovascularization, Pathologic/*drug therapy
MH  - Niacinamide/analogs & derivatives
MH  - Phenylurea Compounds
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Pyridines/therapeutic use
MH  - Pyrroles/therapeutic use
MH  - Sorafenib
MH  - Sunitinib
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
PMC - PMC3096961
EDAT- 2010/11/12 06:00
MHDA- 2013/02/13 06:00
CRDT- 2010/11/12 06:00
PHST- 2010/11/12 06:00 [entrez]
PHST- 2010/11/12 06:00 [pubmed]
PHST- 2013/02/13 06:00 [medline]
AID - bcr2642 [pii]
AID - 10.1186/bcr2642 [doi]
PST - ppublish
SO  - Breast Cancer Res. 2010;12(5):209. doi: 10.1186/bcr2642. Epub 2010 Sep 29.